ICP 022

Drug Profile

ICP 022

Alternative Names: ICP-022

Latest Information Update: 11 Jul 2017

Price : $50

At a glance

  • Originator Innocare Pharma Australia
  • Class Antirheumatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 03 Jul 2017 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in Australia (PO) (NCT03189017)
  • 03 Jul 2017 Phase-I clinical trials in Systemic lupus erythematosus (In volunteers) in Australia (PO) (NCT03189017)
  • 12 Jun 2017 Innocare Pharma Australia plans a phase I trial for Rheumatoid arthritis (In volunteers) and Systemic lupus erythematosus (In volunteers) in Australia (NCT03189017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top